Novartis AG (NVSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novartis AG (NVSN) has a cash flow conversion efficiency ratio of 0.094x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$3.68 Billion ≈ $211.55 Million USD) by net assets (MX$38.93 Billion ≈ $2.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NVSN stock market capitalisation for the company's overall valuation and market capitalisation.
Novartis AG - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Novartis AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novartis AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novartis AG ranked by their cash flow conversion efficiency. Explore Novartis AG earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Construction Bank Corporation
F:C6T
|
-0.064x |
|
Novartis AG ADR
NYSE:NVS
|
0.140x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
|
Royal Bank of Canada
TO:RY
|
0.026x |
|
RTX Corporation
NYSE:RTX
|
0.061x |
|
Roche Holding AG
SW:ROG
|
0.296x |
|
Toyota Motor Corporation ADR
NYSE:TM
|
0.021x |
|
GE Vernova LLC
NYSE:GEV
|
0.344x |
Annual Cash Flow Conversion Efficiency for Novartis AG (2014–2025)
The table below shows the annual cash flow conversion efficiency of Novartis AG from 2014 to 2025. View Novartis AG stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$46.55 Billion ≈ $2.68 Billion |
MX$19.14 Billion ≈ $1.10 Billion |
0.411x | +3.00% |
| 2024-12-31 | MX$44.13 Billion ≈ $2.54 Billion |
MX$17.62 Billion ≈ $1.01 Billion |
0.399x | +16.51% |
| 2023-12-31 | MX$46.75 Billion ≈ $2.69 Billion |
MX$16.02 Billion ≈ $922.07 Million |
0.343x | +43.05% |
| 2022-12-31 | MX$59.42 Billion ≈ $3.42 Billion |
MX$14.24 Billion ≈ $819.29 Million |
0.240x | +7.81% |
| 2021-12-31 | MX$67.82 Billion ≈ $3.90 Billion |
MX$15.07 Billion ≈ $867.34 Million |
0.222x | -7.75% |
| 2020-12-31 | MX$56.67 Billion ≈ $3.26 Billion |
MX$13.65 Billion ≈ $785.56 Million |
0.241x | -1.79% |
| 2019-12-31 | MX$55.55 Billion ≈ $3.20 Billion |
MX$13.62 Billion ≈ $784.12 Million |
0.245x | +35.24% |
| 2018-12-31 | MX$78.69 Billion ≈ $4.53 Billion |
MX$14.27 Billion ≈ $821.36 Million |
0.181x | +6.67% |
| 2017-12-31 | MX$74.23 Billion ≈ $4.27 Billion |
MX$12.62 Billion ≈ $726.34 Million |
0.170x | +10.97% |
| 2016-12-31 | MX$74.89 Billion ≈ $4.31 Billion |
MX$11.47 Billion ≈ $660.39 Million |
0.153x | -0.67% |
| 2015-12-31 | MX$77.12 Billion ≈ $4.44 Billion |
MX$11.90 Billion ≈ $684.68 Million |
0.154x | -21.36% |
| 2014-12-31 | MX$70.84 Billion ≈ $4.08 Billion |
MX$13.90 Billion ≈ $799.78 Million |
0.196x | -- |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more